Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Overview
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Chengdu Zenitar Biomedical Technology Co Ltd
Concert Pharmaceuticals Inc
Cothera Bioscience Pty Ltd
CTI BioPharma Corp
Eli Lilly and Co
Hangzhou East Chi Pharmaceutical Group Co Ltd
HK inno.N Corp
Incyte Corp
Japan Tobacco Inc
Kiset Therapeutics Inc
Merck & Co Inc
Novartis AG
NS Pharma Inc
OHM Oncology
Pfizer Inc
Shanghai Xunhe Pharmaceutical Technology Co Ltd
Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd
Sierra Oncology Inc
Simcere Pharmaceutical Group Ltd
Sino Biopharmaceutical Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Theravance Biopharma Inc
Turning Point Therapeutics Inc
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Drug Profiles
A-223 - Drug Profile
Product Description
Mechanism Of Action
baricitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
CHZ-868 - Drug Profile
Product Description
Mechanism Of Action
CJ-15314 - Drug Profile
Product Description
Mechanism Of Action
History of Events
delgocitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
deuruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
fedratinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
filgotinib maleate - Drug Profile
Product Description
Mechanism Of Action
FLLL-12 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ilgitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
jaktinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
MA-2014 - Drug Profile
Product Description
Mechanism Of Action
momelotinib dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
OB-756 - Drug Profile
Product Description
Mechanism Of Action
OHM-581 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Opzelura - Drug Profile
Product Description
Mechanism Of Action
History of Events
pacritinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
repotrectinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
SAR-317461 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit AURKA, EGFR and JAK2 for Gastrointestil Tract Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK2 for Autoimmune Disorders and Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit BRD4 and JAK2 for Myelofibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit JAK1, JAK2, JAK3 and TYK2 for Dermatology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit JAK2 and FLT3 for Myelofibrosis and Acute Myeloid Leukemia - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit JAK2 for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit JAK2 for Myelofibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Moleucle to Inhibit JAK 1 and JAK 2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
TQ-05105 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VR-588 - Drug Profile
Product Description
Mechanism Of Action
History of Events
zotiraciclib citrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kise JAK2 (Janus Kise 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Mar 07, 2022: Another lifesaving COVID-19 drug identified
Mar 04, 2022: VONJO (pacritinib) now approved for the treatment of adults with intermediate or high-risk primary or secondary myelofibrosis with a platelet count below 50 x 109/L
Mar 01, 2022: DRI Healthcare Trust comments on FDA approval of VONJOTM (pacritinib)
Feb 28, 2022: CTI BioPharma announces FDA accelerated approval of VONJO (pacritinib) for the treatment of adult patients with Myelofibrosis and Thrombocytopenia
Feb 17, 2022: Zai Lab announces breakthrough therapy desigtion granted for Repotrectinib in Chi
Feb 17, 2022: WHO recommends Baricitinib for Covid-19
Jan 28, 2022: Updates on OLUMIANT (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis
Jan 25, 2022: Sierra Oncology provides fincial update to support the future commercialization of momelotinib
Jan 25, 2022: Sierra Oncology announces momelotinib achieved statistically significant benefit on symptoms, anemia and splenic size in the pivotal MOMENTUM study for myelofibrosis
Jan 19, 2022: Momelotinib review article published in Jourl of Hematology & Oncology highlights importance of anemia benefit for Myelofibrosis Patients
Jan 18, 2022: Sierra Oncology updates topline data timing for pivotal phase 3 trial of momelotinib in myelofibrosis
Jan 17, 2022: MSF responds to latest WHO recommendation for COVID-19 medicine baricitinib
Jan 14, 2022: WHO recommends Eli Lilly drug to treat COVID-19
Jan 04, 2022: Concert Pharmaceuticals completes enrollment in THRIVE-AA2 phase 3 clinical trial evaluating CTP-543 for Alopecia Areata
Dec 14, 2021: Incyte announces acceptance and Priority Review of sNDA for ruxolitinib cream (Opzelura) as a treatment for patients with vitiligo
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Indications, 2022 (Contd..3)
Number of Products under Development by Indications, 2022 (Contd..4)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Companies, 2022 (Contd..7)
Products under Development by Companies, 2022 (Contd..8)
Products under Development by Companies, 2022 (Contd..9)
Products under Development by Companies, 2022 (Contd..10)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Chengdu Zenitar Biomedical Technology Co Ltd, 2022
Pipeline by Concert Pharmaceuticals Inc, 2022
Pipeline by Cothera Bioscience Pty Ltd, 2022
Pipeline by CTI BioPharma Corp, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, 2022
Pipeline by HK inno.N Corp, 2022
Pipeline by Incyte Corp, 2022
Pipeline by Japan Tobacco Inc, 2022
Pipeline by Kinaset Therapeutics Inc, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Novartis AG, 2022
Pipeline by NS Pharma Inc, 2022
Pipeline by OHM Oncology, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Shanghai Xunhe Pharmaceutical Technology Co Ltd, 2022
Pipeline by Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd, 2022
Pipeline by Sierra Oncology Inc, 2022
Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Pipeline by Sino Biopharmaceutical Ltd, 2022
Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
Pipeline by Theravance Biopharma Inc, 2022
Pipeline by Turning Point Therapeutics Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Dormant Products, 2022 (Contd..4)
Dormant Products, 2022 (Contd..5)
Dormant Products, 2022 (Contd..6)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)